Independent Franchise Partners LLP Purchases 4,217,570 Shares of Solventum Corporation $SOLV

Key Points

• Independent Franchise Partners LLP increased its holdings in Solventum Corporation by 263.1%, acquiring an additional 4,217,570 shares, bringing their total to 5,820,724 shares.
• Solventum reported an EPS of $1.69 for the last quarter, exceeding analyst estimates of $1.45, with revenue of $2.16 billion, an increase of 3.8% year-over-year.
• Several analysts have revised their ratings and price targets for Solventum, including Morgan Stanley, which upgraded the stock from "equal weight" to "overweight" with a target of $103.00.

Independent Franchise Partners LLP boosted its position in Solventum Corporation (NYSE:SOLV - Free Report) by 263.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,820,724 shares of the company's stock after purchasing an additional 4,217,570 shares during the period. Solventum makes up approximately 3.2% of Independent Franchise Partners LLP's investment portfolio, making the stock its 17th biggest holding. Independent Franchise Partners LLP owned approximately 3.36% of Solventum worth $442,608,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Trian Fund Management L.P. lifted its stake in Solventum by 18.8% in the fourth quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock worth $559,054,000 after purchasing an additional 1,336,564 shares during the last quarter. Davis Selected Advisers increased its position in shares of Solventum by 0.8% during the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock worth $402,110,000 after acquiring an additional 41,524 shares during the period. Boston Partners increased its position in shares of Solventum by 101.3% during the first quarter. Boston Partners now owns 3,361,973 shares of the company's stock worth $255,554,000 after acquiring an additional 1,691,565 shares during the period. Northern Trust Corp increased its position in shares of Solventum by 3.3% during the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock worth $137,456,000 after acquiring an additional 58,373 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Solventum by 2.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company's stock valued at $89,268,000 after buying an additional 24,762 shares during the period.

Solventum Trading Up 2.0%

NYSE:SOLV opened at $73.46 on Friday. Solventum Corporation has a 12 month low of $59.35 and a 12 month high of $85.92. The firm has a fifty day simple moving average of $73.79 and a 200-day simple moving average of $72.86. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $12.74 billion, a P/E ratio of 34.01, a PEG ratio of 1.78 and a beta of 0.52.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The business's revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. KeyCorp initiated coverage on shares of Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock. Wells Fargo & Company lifted their price target on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price target (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Finally, Wall Street Zen lowered shares of Solventum from a "strong-buy" rating to a "buy" rating in a report on Sunday. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Solventum currently has a consensus rating of "Hold" and an average price target of $85.75.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.